Orgenesis (ORGS) 10-Q 14 Apr 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Feb. 29, 2016	Apr. 14, 2016
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Feb. 29, 2016
Trading Symbol	orgs
Entity Registrant Name	Orgenesis Inc.
Entity Central Index Key	1,460,602
Current Fiscal Year End Date	--11-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		108,739,806
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Feb. 29, 2016	Nov. 30, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 933	$ 4,168
Accounts receivable	1,694	1,173
Prepaid expenses and other receivables	973	1,118
Grants receivable	1,037	1,446
Inventory	418	301
Total current assets	5,055	8,206
NON CURRENT ASSETS:
Property and equipment, net	4,564	4,296
Restricted cash	5	5
Intangible assets, net	16,707	16,653
Goodwill	9,812	9,535
Other assets	57	53
Total non current assets	31,145	30,542
TOTAL ASSETS	36,200	38,748
CURRENT LIABILITIES:
Accounts payable	2,865	3,475
Accrued expenses	992	816
Employee and related payables	1,643	1,348
Related parties	42	42
Advance payments on account of grant	247	307
Short-term loans and current maturities of long term loans	1,211	2,829
Deferred income	1,415	1,216
Convertible loans	2,013	3,022
Convertible bonds	1,787	1,888
Price protection derivative	197	1,533
TOTAL CURRENT LIABILITIES	12,412	16,476
LONG-TERM LIABILITIES:
Loans payable	2,534	2,540
Warrants	1,450	1,382
Retirement benefits obligation	5	5
Deferred taxes	3,117	3,327
TOTAL LONG-TERM LIABILITIES	7,106	7,254
TOTAL LIABILITIES	$ 19,518	$ 23,730
COMMITMENTS
REDEEMABLE COMMON STOCK	$ 0	$ 21,458
EQUITY (CAPITAL DEFICIENCY):
Common stock	11	6
Additional paid-in capital	37,801	14,229
Receipts on account of shares to be allotted	67	1,251
Accumulated other comprehensive loss	(782)	(1,286)
Accumulated deficit	(20,415)	(20,640)
TOTAL EQUITY (CAPITAL DEFICIENCY)	16,682	(6,440)
TOTAL LIABILITIES AND EQUITY (NET OF CAPITAL DEFICIENCY)	$ 36,200	$ 38,748

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	3 Months Ended
	Feb. 29, 2016	Feb. 28, 2015
REVENUES	$ 1,520	$ 0
COST OF REVENUES	1,480	0
GROSS PROFIT	40	0
RESEARCH AND DEVELOPMENT EXPENSES, net	401	175
AMORTIZATION OF INTANGIBLE ASSETS	328	0
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	1,166	659
OPERATING LOSS	(1,855)	(834)
FINANCIAL INCOME, net	1,772	44
LOSS BEFORE INCOME TAXES	(83)	(790)
INCOME TAX BENEFIT	308	0
NET INCOME (LOSS)	$ 225	$ (790)
EARNING (LOSS) PER SHARE:
Basic	$ 0.002	$ (0.01)
Diluted	$ 0.001	$ (0.02)
WEIGHTED AVERAGE NUMBER OF SHARES USED IN COMPUTATION OF BASIC AND DILUTED EARNING (LOSS) PER SHARE:
Basic	103,127,025	55,735,394
Diluted	103,127,025	56,288,938
OTHER COMPREHENSIVE INCOME (LOSS):
Net income (loss)	$ 225	$ (790)
Translation adjustments	504	(102)
TOTAL COMPREHENSIVE INCOME (LOSS)	$ 729	$ (892)

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY/EQUITY - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Receipts on Account of Share to be Allotted [Member]	Accumulated Other Comprehensive Loss[Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Nov. 30, 2014	$ 6	$ 13,152	$ 60	$ (18)	$ (16,179)	$ (2,979)
Beginning Balance (Shares) at Nov. 30, 2014	55,970,565
Stock-based compensation to employees and directors		159				159
Stock-based compensation to service providers		90				90
Comprehensive loss for the period				(102)	(790)	(892)
Ending Balance at Feb. 28, 2015	$ 6	13,401	60	(120)	(16,969)	(3,622)
Ending Balance (Shares) at Feb. 28, 2015	55,970,565
Beginning Balance at Nov. 30, 2015	$ 6	14,229	1,251	(1,286)	(20,640)	(6,440)
Beginning Balance (Shares) at Nov. 30, 2015	55,835,950
Stock-based compensation to employees and directors		120				120
Stock-based compensation to service providers		50				50
Issuance of shares from investments and conversion of convertible loans	$ 1	1,948	(1,251)			698
Issuance of shares from investments and conversion of convertible loans (Shares)	10,502,132
Reclassification of redeemable common stock	$ 4	21,454				21,458
Reclassification of redeemable common stock (Shares)	42,401,724
Receipts on account of shares to be allotted			67			67
Comprehensive loss for the period				504	225	729
Ending Balance at Feb. 29, 2016	$ 11	$ 37,801	$ 67	$ (782)	$ (20,415)	$ 16,682
Ending Balance (Shares) at Feb. 29, 2016	108,739,806

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Feb. 29, 2016	Feb. 28, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 225	$ (790)
Adjustments required to reconcile net loss to net cash used in operating activities:
Stock-based compensation	170	249
Depreciation and amortization expenses	641	1
Change in fair value of warrants and embedded derivatives	(1,803)	(183)
Change in fair value of convertible bonds	(157)	0
Interest expense accrued on loans and convertible loans	8	116
Changes in operating assets and liabilities:
Increase in accounts receivable	(489)	0
Increase in inventory	(109)	0
Increase in other assets	(2)	0
Decrease (increase) in prepaid expenses and other accounts receivable	164	(610)
Decrease in accounts payable	(692)	(515)
Increase (decrease) in accrued expenses	172	(128)
Increase (decrease) in employee and related payables	286	(77)
Increase in deferred income	165	0
Decrease in advance payments and receivables on account of grant	388	1,296
Decrease in deferred taxes	(308)	0
Net cash used in operating activities	(1,341)	(641)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(354)	(6)
Restricted cash	0	(5)
Net cash used in investing activities	(354)	(11)
CASH FLOWS FROM FINANCING ACTIVITIES:
Short-term line of credit	0	(14)
Proceeds from issuance of warrants into shares and warrants	225	0
Repayment of short and long-term debt	(1,733)	0
Net cash used in financing activities	(1,508)	(14)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(3,203)	(666)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(32)	(128)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	4,168	1,314
CASH AND CASH EQUIVALENTS AT END OF PERIOD	933	520
SUPPLEMENTAL NON-CASH FINANCING ACTIVITY
Conversion of loans (including accrued interest) to common stock and warrants	973	0
Reclassification of redeemable common stock to equity	21,458	0
SUPPLEMENTAL INFORMATION ON INTEREST PAID IN CASH	$ 136	$ 0

GENERAL AND BASIS OF PRESENTATI

GENERAL AND BASIS OF PRESENTATION	3 Months Ended
	Feb. 29, 2016
GENERAL AND BASIS OF PRESENTATION [Text Block]	NOTE 1 - GENERAL AND BASIS OF PRESENTATION Orgenesis Inc. (“the Company”) was incorporated in the state of Nevada on June 5, 2008. The Company is developing a technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into “pancreatic beta cell-like” insulin producing cells for patients with Type 1 Diabetes. As discussed in Note 3, on March 2, 2015, the Company completed the acquisition of MaSTherCell SA and Cell Therapy Holding SA (collectively “MaSTherCell”). MaSTherCell is a Contract Development and Manufacturing Organization (“CDMO”) specializing in cell therapy development for advanced medicinal products. Cell therapy is the prevention or treatment of human disease by the administration of cells that have been selected, multiplied and pharmacologically treated or altered outside the body (ex vivo). MaSTherCell's CDMO activity is operated as a separate reporting segment (See Note 4). As used in this report and unless otherwise indicated, the term “Company” refers to Orgenesis Inc. and its wholly-owned subsidiaries (“Subsidiaries”). Unless otherwise specified, all amounts are expressed in United States dollars. Basis of Presentation These unaudited condensed consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with U.S. GAAP, pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial statements. Accordingly, they do not contain all information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of February 29, 2016, and the consolidated statements of comprehensive income (loss) for the three months ended February 29, 2016 and February 28, 2015, and the changes in equity (capital deficiency) and cash flows for the three-months periods ended February 29, 2016 and February 28, 2015. The results for the three months ended February 29, 2016 are not necessarily indicative of the results to be expected for the year ending November 30, 2016. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended November 30, 2015. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has net losses for the period from inception (June 5, 2008) through February 29, 2016 of $20.4 million, as well as negative cash flows from operating activities. Presently, the Company does not have sufficient cash resources to meet its plans in the twelve months following February 29, 2016. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management is in the process of evaluating various financing alternatives for operations, as the Company will need to finance future research and development activities and general and administrative expenses through fund raising in the public or private equity markets. The consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability. If the Company raises additional funds through the issuance of equity, the percentage ownership of current shareholders could be reduced, and such securities might have rights, preferences or privileges senior to its common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective business endeavors or opportunities, which could significantly and materially restrict its future plans for developing its business and achieving commercial revenues. If the Company is unable to obtain the necessary capital, the Company may have to cease operations.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Feb. 29, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Text Block]	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Newly Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09) "Revenue from Contracts with Customers." ASU 2014-09 will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2016 (early adoption is not permitted). The guidance permits the use of either a retrospective or cumulative effect transition method. On July 9, 2015, the FASB decided to delay the effective date of the new revenue standard by one year. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating the impact of this standard. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” Continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Prior to this, there was no guidance under U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this update provide that guidance. In doing so, the amendments reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term “substantial doubt”, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). For the period ended November 30, 2015, management evaluated the Company’s ability to continue as a going concern and concluded that substantial doubt has not been alleviated about the Company’s ability to continue as a going concern. While the Company continues to explore further significant sources of financing, management’s assessment was based on the uncertainty related to the availability, amount and nature of such financing over the next twelve months. In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued ASU 2016-06, Contingent Put and Call Options in Debt Instruments (Topic 815), which requires that embedded derivatives be separated from the host contract and accounted for separately as derivatives if certain criteria are met. One of those criteria is that the economic characteristics and risks of the embedded derivatives are not clearly and closely related to the economic characteristics and risks of the host contract (the “clearly and closely related” criterion). The amendments in this Update clarify what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts, which is one of the criteria for bifurcating an embedded derivative. Consequently, when a call (put) option is contingently exercisable, an entity does not have to assess whether the event that triggers the ability to exercise a call (put) option is related to interest rates or credit risks. The amendments are an improvement to GAAP because they eliminate diversity in practice in assessing embedded contingent call (put) options in debt instruments. The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted for all entities. The Company is currently evaluating the impact of this new standard on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, as part of its Simplification Initiative. The areas for simplification in this Update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the areas for simplification apply only to nonpublic entities. The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early application is permitted for all entities. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

ACQUISITION OF MASTHERCELL

ACQUISITION OF MASTHERCELL	3 Months Ended
	Feb. 29, 2016
ACQUISITION OF MASTHERCELL [Text Block]	NOTE 3 – ACQUISITION OF MASTHERCELL Description of the Transaction The Company entered into a share exchange agreement (the "Share Exchange Agreement") dated March 2, 2015 with MaSTherCell SA, Cell Therapy Holding SA (collectively “MaSTherCell”). According to the Share Exchange Agreement, in exchange for all of the issued and outstanding shares of MaSTherCell, the Company issued to the shareholders of MaSTherCell an aggregate of 42,401,724 shares (the “Consideration Shares”) of common stock at a price of $0.58 per share for an aggregate price of $24,593 thousand). Out of the Consideration Shares, 8,173,483 shares will be allocated to the bondholders of MaSTherCell in case of conversion. As part of the agreement the parties agreed on certain post closing conditions. In the event that the Company did not achieve those conditions within eight (8) months of the closing date, MaSTherCell had an option to unwind the transaction. (the “Unwind Option”) by delivering to the Company all of the Consideration Shares plus any amount that the Company has advanced or invested in MaSTherCell. On November 12, 2015, the Company and MaSTherCell and each of the shareholders of MaSTherCell (the “MaSTherCell Shareholders”), entered into an amendment (“Amendment No. 2”) to the Share Exchange Agreement. Under Amendment No. 2, the MaSTherCell Shareholders option to unwind the transaction was extended to November 30, 2015, furthermore the Company agreed to remit to MaSTherCell, by way of an equity investment, the sum of EUR3.8 million by November 30, 2015 (the “Initial Investment”), to be followed by a subsequent equity investment by December 31, 2015 in MaSTherCell of EUR1.2 million. The extended right of the MaSTherCell Shareholders to unwind the transaction could have been exercised by them only if the Company had not achieved the Post Closing Financing and/or completed the Initial Investment (as defined) by November 30, 2015. On December 10, 2015, the Company entered into definitive agreements with accredited investors relating to a private placement for aggregate proceeds to the Company of $4,278 thousand. From the proceeds of the Private Placement, on December 10, 2015 the Company remitted to MaSTherCell the Initial Investment of € 3.8 million or $4,103 thousand (out of the original obligation for investment of €5 million), in compliance with its obligations as required under the Share Exchange Agreement. As a result, the Unwind Option was canceled and all the shares that were issued, have been reclassed from redeemable common stock into equity.

SEGMENT INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Feb. 29, 2016
SEGMENT INFORMATION [Text Block]	NOTE 4 - SEGMENT INFORMATION The Chief Executive Officer ("CEO") is the Company’s chief operating decision-maker ("CODM"). Following the acquisition of MaSTherCell, management has determined that there are two operating segments, based on the Company's organizational structure, its business activities and information reviewed by the CODM for the purposes of allocating resources and assessing performance. CDMO The CDMO activity is operated by MaSTherCell, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: (i) process and assay development services and (ii) GMP contract manufacturing services. The CDMO segment includes only the results of MaSTherCell. CTB The Cellular Therapy Business (“CTB”) activity is based on the Company's technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into “pancreatic beta cell-like” insulin producing cells for patients with Type 1 Diabetes. This segment is comprised of all entities aside from MaSTherCell. The Company assesses the performance based on a measure of "Adjusted EBIT" (earnings before financial expenses and tax, and excluding share-based compensation expenses and non-recurring income or expenses). The measure of assets has not been disclosed for each segment. Prior to the acquisition of MaSTherCell, the Company operated as one reporting segment. For this reason, the Company does not disclose comparative data for the three months ended February 28, 2015. Segment data for the three months ended February 29, 2016 is as follows: Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 1,571 $ $ (51 ) $ 1,520 Cost of revenues (1,288 ) 119 (1,169 ) Research and development expenses, net (298 ) (68 ) (366 ) Operating expenses (607 ) (422 ) (1,029 ) Depreciation and amortization expense (640 ) (1 ) (641 ) Segment Performance $ (964 ) $ (721 ) (1,685 ) Share-based compensation (170 ) (170 ) Financial income, net 1,772 1,772 Loss before income taxes (83 ) Geographic, Product and Customer Information Substantially all of the Company's revenues and long lived assets are located in Belgium. Net revenues from single customers from the CDMO segment that exceed 10% of total net revenues are: Three months ended February 29, 2016 (in thousands) Customer A $ 764 Customer B $ 562

CONVERTIBLE LOAN AGREEMENTS

CONVERTIBLE LOAN AGREEMENTS	3 Months Ended
	Feb. 29, 2016
CONVERTIBLE LOAN AGREEMENTS [Text Block]	NOTE 5 – CONVERTIBLE LOAN AGREEMENTS During the year ended November 30, 2015, the Company entered into five convertible loan agreements with new investors for a total amount of $950 thousand (the “2015 Convertible Loans”), interest is calculated at 6% annually and was payable, along with the principal on or before the maturity date. On December 23, 2015, the holders of all the 2015 Convertible Loans and the Company agreed to convert the 2015 Convertible Loans and accrued interest into units of the Company’s common stock, each unit comprising one share of the Company’s common stock and one three-year warrant to purchase an additional share of the Company’s common stock at an exercise price of $0.52. Upon conversion of the 2015 Convertible Loans, the Company issued an aggregate of 1,870,638 shares of Common stock and three year warrants to purchase up to an additional 1,870,638 shares. Furthermore, in the event the Company issues any common shares or securities convertible into common shares in a private placement for cash at a price less than $0.52 (the “New Issuance Price”) before December 23, 2016, the Company will issue, for no additional consideration, additional common shares to subscribers, according to the mechanism defined in the agreements. This provision does not apply to issuance of shares under options, issuance of shares under existing rights to acquire shares, nor issuance of shares for non-cash consideration. The Company allocated the principal amount of the convertible loans and the accrued interest thereon based on their fair value. The table below presents the fair value of the instruments issued as of the conversion date and the allocation of the proceeds (for the fair value as of February 29, 2016, see Note 9): Total Fair Value (in thousands) Warrants component $ 323 Price protection derivative component 34 Shares component 616 Total $ 973

COMMITMENTS

COMMITMENTS	3 Months Ended
	Feb. 29, 2016
COMMITMENTS [Text Block]	NOTE 6 – COMMITMENTS Collaboration Agreements On March 14, 2016, the Israel subsidiary, entered into a collaboration agreement with CureCell Co., Ltd. (“CureCell”), initially for the purpose of applying for a grant from the Korea Israel Industrial R&D Foundation ("Koril-RDF") for pre-clinical and clinical activities related to the commercialization of Orgenesis Ltd.’s AIP cell therapy product in Korea ("Koril Grant"). Subject to receiving the Koril Grant, the Parties shall carry out at their own expense their respective commitments under the work plan approved by Koril-RDF and any additional work plan to be agreed between the Israeli Subsidiary and CureCell. The Israeli Subsidiary will own sole rights to any intellectual property developed from the collaboration which is derived under the Israeli Subsidiary’s AIP cell therapy product, information licensed from THM. Subject to obtaining the requisite approval needed to commence commercialization in Korea, the Israel subsidiary has agreed to grant to CureCell, or a fully owned subsidiary thereof, under a separate sub-license agreement an exclusive sub-license to the intellectual property underlying the Company’s API product solely for commercialization of the Israel subsidiary products in Korea. As part of any such license CureCell has agreed to pay annual license fees, ongoing royalties based on net sales generated by CureCell and its sublicensees, milestone payments and sublicense fees. Under the agreement, CureCell is entitled to share in the net profits derived by the Israeli Subsidiary from world - On March 14, 2016, the Company and CureCell Co., Ltd. (“CureCell”) of Korea entered into a Joint Venture Agreement (the “JVA”) pursuant to which the parties will collaborate in the contract development and manufacturing of cell therapy products in Korea. The parties intend to pursue the joint venture through a newly established Korean company (the “JV Company”) which the Company by itself, or together with a designee, will hold a 50% participating interest therein, with the remaining 50% participating interest being held by CureCell. Under the JVA, CureCell is to procure, at its sole expense, a GMP facility and appropriate staff in Korea for the manufacture of the cell therapy products. The Company will share with CureCell the Company’s know-how in the field of cell therapy manufactuing, which know-how will not include the intellectual property included in the license from the Tel Hashomer Hospital in Israel to the Israeli subsidiary. In addition, each party shall be required to perform its respective obligations according to a detailed work plan to be agreed upon by CureCell and Company within no later than 30 days following the execution of the JVA. Under the JVA, the Company and CureCell each undertook to remit, within two years of the execution of the JVA, $2 million to the JV Company, of which $1 million is to be in cash and the balance in an in-kind investment, the scope and valuation of which shall be preapproved in writing by CureCell and the Company. The Company’s funding will be made by way of a convertible loan to the JV Company or the joint venture (if the JV Company is not established). The JVA provides that, under certain specified conditions, the Company can require CureCell to sell to the Company its participating (including equity) interest in the JV Company in consideration for the issuance of the Company’s common stock based on the then valuation of the JV Company.

EQUITY

EQUITY	3 Months Ended
	Feb. 29, 2016
EQUITY [Text Block]	NOTE 7 – EQUITY a. Share Capital The Company’s common shares are traded on the OTC Market Group’s OTCQB tier under the symbol “ORGS”. b. Financings During the first quarter of 2016, the Company entered into definitive agreements with accredited investors relating to a private placement (the “Private Placement”) of (i) 432,693 shares of the Company’s common stock and (ii) three year warrants to purchase up to an additional 432,693 shares of the Company’s Common Stock at a per share exercise price of $0.52. The purchased securities were issued pursuant to subscription agreements between the Company and the purchasers for aggregate proceeds to the Company of $225 thousand. Furthermore, in the event the Company issues any common shares or securities convertible into common shares in a private placement for cash at a price less than $0.52 (the “New Issuance Price”) within a year from the issuance date, the Company will issue, for no additional consideration, additional common shares to subscribers in the $0.52 per share which total each subscriber’s subscription proceeds divided by the New Issuance Price, minus the number of shares already issued to such subscriber. This provision does not apply to issuance of shares under options, issuance of shares under existing rights to acquire shares, nor issuance of shares for non-cash consideration (See also Note 9). The Company allocated the proceeds from the private placement based on the fair value of the warrants and the price protection derivative components. The residual amount was allocated to the shares. The table below presents the fair value of the instruments issued as of the closing dates and the allocation of the proceeds (for the fair value as of February 29, 2016, see Note 9): Total Fair Value (in thousands) Warrants component $ 67 Price protection derivative component 9 Shares component 149 Total $ 225

LOSS PER SHARE

LOSS PER SHARE	3 Months Ended
	Feb. 29, 2016
LOSS PER SHARE [Text Block]	NOTE 8 – EARNING ( LOSS) PER SHARE The following table sets forth the calculation of basic and diluted earning (loss) per share for the periods indicated: Three Months Ended February 29, February 28, 2016 2015 (in thousands, except per share data) Basic: Income (loss) for the period $ 225 $ (790 ) Weighted average number of common shares outstanding 103,127,025 55,735,394 Earning (loss) per common share $ 0.002 $ (0.01 ) Diluted Income (loss) for the period $ 225 (790 ) Changes in fair value of embedded (104 ) Change in fair value of warrants 153 Income (loss) for the period $ 121 (943 ) Weighted average number of shares 103,127,025 55,735,394 Number of dilutive shares related to warrants 553,543 Weighted average number of common shares outstanding 103,127,025 56,288,937 Earning (loss) per common share $ 0.001 $ (0.02 ) Diluted earning per share does not include 12,899,314 shares underlying outstanding options, 17,933,512 shares issuable upon exercise of warrants and 1,100,000 shares upon conversion of convertible notes for the three months ended February 29, 2016, because the effect of their inclusion in the computation would be anti-dilutive. Diluted loss per share does not include 15,267,559 shares underlying outstanding options, 350,000 shares due to stock-based compensation to service providers, 2,682,256 shares issuable upon exercise of warrants and 701,796 shares upon conversion of loans for the three months ended February 28, 2015, because the effect of their inclusion in the computation would be anti-dilutive.

FAIR VALUE PRESENTATION

FAIR VALUE PRESENTATION	3 Months Ended
	Feb. 29, 2016
FAIR VALUE PRESENTATION [Text Block]	NOTE 9 - FAIR VALUE PRESENTATION The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: • Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. • Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. • Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs, to the extent possible, and considers credit risk in its assessment of fair value. As of February 29, 2016 and November 30, 2015 the Company’s liabilities that are measured at fair value and classified as level 3 fair value are as follows (in thousands): February 29, November 30, 2016 2015 Level 3 Level 3 Warrants (1) $ 1,450 $ 1,382 Price protection derivative (1) 197 1,533 Embedded derivatives*(1) 177 289 Convertible bonds (2) $ 1,787 $ 1,888 * The embedded derivative is presented in the Company's balance sheets on a combined basis with the related host contract (the convertible loans). (1) The fair value of the warrants, price protection derivatives and embedded derivatives is determined by using a Monte Carlo Simulation Model. This model, in contrast to the closed form model, such as the Black-Scholes Model, enables the Company to take into consideration the conversion price changes over the conversion period of the loan, and therefore is more appropriate in this case. (2) The fair value of the convertible bonds described in Note 7 of the Annual Report and is determined by using a binomial model for the valuation of the embedded derivative and the fair value of the bond was calculated based on the effective rate on the valuation date ( 6%). The binomial model used the forecast of the Company share price during the convertible bond's contractual term. Since the convertible bond is in Euro and the model is in USD, the Company has used the Euro/USD forward rates for each period. In order to solve for the embedded derivative fair value, the calculation was performed as follows: • Stage A - The model calculates a number of potential future share prices of the Company based on the volatility and risk-free interest rate assumptions. • Stage B - the embedded derivative value is calculated "backwards" in a way that takes into account the maximum value between holding the bonds until maturity or converting the bonds. The following table presents the assumptions that were used for the models as of February 29, 2016: Price Protection Embedded Derivative and Derivative Warrants Fair value of shares of common stock $ 0.33 $ 0.33 Expected volatility 84% - 89% 84% Discount on lack of marketability 13% - Risk free interest rate 0.38% - 0.9% 0.38% Expected term (years) 0.7 - 2.9 0.33 Expected dividend yield 0% 0% Expected capital raise dates Q2 2016,Q3 2016, Q1 2018 * The following table presents the assumptions that were used for the models as of November 30, 2015: Price Protection Derivative and Embedded Convertible Warrants Derivative Bonds Fair value of shares of common stock $ 0.33 $ 0.33 $ 0.33 Expected volatility 87% - 98% 87% 88% Discount on lack of marketability 14% - 18% Risk free interest rate 0.44% - 1.24% 0.11% - 0.49% 0.42% Expected term (years) 0.9 - 3 0.08 - 0.87 0.8 Expected dividend yield 0% 0% 0% Expected capital raise dates Q2 2016-Q4 2016, Q4 2017 The table below sets forth a summary of the changes in the fair value of the Company’s financial liabilities classified as Level 3 for the three months ended February 29, 2016: Price Embedded Convertible Protection Warrants Derivatives Bonds Derivative (in thousands) Balance at beginning of the period $ 1,382 $ 289 $ 1,888 $ 1,533 Additions 390 43 Conversion (10 ) Changes in fair value during the period (322 ) (102 ) (157 ) (1,379 ) Translation adjustments 56 Balance at end of the period $ 1,450 $ 177 $ 1,787 $ 197 (*) There were no transfers to Level 3 during the three months ended February 29, 2016. The Company has performed a sensitivity analysis of the results for the warrants fair value to changes in the assumptions for expected volatility with the following parameters: Base -10% Base Base+10% (in thousands) As of February 29, 2016 $ 1,268 $ 1,450 $ 1,618 The Company has performed a sensitivity analysis of the results for the price protection derivative fair value to changes in the assumptions expected volatility with the following parameters: Base -10% Base Base+10% (in thousands) As of February 29, 2016 $ 192 $ 196 $ 199 The Company has performed a sensitivity analysis of the results for the Embedded Derivative fair value to changes in the assumptions expected volatility with the following parameters: Base -10% Base Base+10% (in thousands) As of February 29, 2016 $ 168.1 $ 177 $ 185.8 The table below sets forth a summary of the changes in the fair value of the Company’s financial liabilities classified as Level 3 for the year ended November 30, 2015: Price Embedded Convertible Protection Warrants Derivatives Bonds Derivative (in thousands) Balance at beginning of the year $ 560 $ 992 $ - $ - Additions 1,390 112 3,234 1,526 Changes in fair value related to warrants expired* (525 ) 7 Changes in fair value during the period (43 ) (814 ) (1,221 ) Translation adjustments (125 ) Balance at end of the year $ 1,382 $ 289 $ 1,888 $ 1,533 (*) During the twelve months ended November 30, 2015, 1,826,718 warrants have expired. There were no transfers to Level 3 during the twelve months ended November 30, 2015.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Feb. 29, 2016
SUBSEQUENT EVENTS [Text Block]	NOTE 10 - SUBSEQUENT EVENTS a. On March 11, 2016, the Company entered into definitive agreement with an investor relating to a private placement of (i) 769,232 shares of the Company’s common stock and (ii) three year warrants to purchase up to an additional 769,232 shares of the Company’s common stock at a per share exercise price of $0.52. The purchased securities will be issued pursuant to subscription agreements between the Company and the purchaser for aggregate proceeds to the Company of $400 thousand. Furthermore, in the event the Company issues any common shares or securities convertible into common shares in a private placement for cash at a price less than $0.52 (the “New Issuance Price”) through the first anniversary of the issuance date, the Company will issue, for no additional consideration, additional common shares to subscribers in the $0.52 per share which total each subscriber’s subscription proceeds divided by the New Issuance Price, minus the number of shares already issued to such subscriber. This provision does not apply to issuance of shares under options, issuance of shares under existing rights to acquire shares, nor issuance of shares for non-cash consideration. b. In April 2016, the Belgian Subsidiary received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DGO6) for a budgeted EUR1,304 thousand support program for the development of a potential cure for Type 1 Diabetes. The financial support is awarded to the Belgium subsidiary as a recoverable advance payment at 55% of budgeted costs, or for a total of EUR717 thousand. The grant will be paid to Orgenesis over a period of 1 year.

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Feb. 29, 2016
Newly Issued Accounting Pronouncements [Policy Text Block]	Newly Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09) "Revenue from Contracts with Customers." ASU 2014-09 will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2016 (early adoption is not permitted). The guidance permits the use of either a retrospective or cumulative effect transition method. On July 9, 2015, the FASB decided to delay the effective date of the new revenue standard by one year. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating the impact of this standard. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” Continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Prior to this, there was no guidance under U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this update provide that guidance. In doing so, the amendments reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term “substantial doubt”, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). For the period ended November 30, 2015, management evaluated the Company’s ability to continue as a going concern and concluded that substantial doubt has not been alleviated about the Company’s ability to continue as a going concern. While the Company continues to explore further significant sources of financing, management’s assessment was based on the uncertainty related to the availability, amount and nature of such financing over the next twelve months. In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, Leases In March 2016, the FASB issued ASU 2016-06, Contingent Put and Call Options in Debt Instruments (Topic 815), which requires that embedded derivatives be separated from the host contract and accounted for separately as derivatives if certain criteria are met. One of those criteria is that the economic characteristics and risks of the embedded derivatives are not clearly and closely related to the economic characteristics and risks of the host contract (the “clearly and closely related” criterion). The amendments in this Update clarify what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts, which is one of the criteria for bifurcating an embedded derivative. Consequently, when a call (put) option is contingently exercisable, an entity does not have to assess whether the event that triggers the ability to exercise a call (put) option is related to interest rates or credit risks. The amendments are an improvement to GAAP because they eliminate diversity in practice in assessing embedded contingent call (put) options in debt instruments. The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted for all entities. The Company is currently evaluating the impact of this new standard on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, as part of its Simplification Initiative. The areas for simplification in this Update involve several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. Some of the areas for simplification apply only to nonpublic entities. The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early application is permitted for all entities. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	3 Months Ended
	Feb. 29, 2016
Schedule of Segment Information [Table Text Block]	Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 1,571 $ $ (51 ) $ 1,520 Cost of revenues (1,288 ) 119 (1,169 ) Research and development expenses, net (298 ) (68 ) (366 ) Operating expenses (607 ) (422 ) (1,029 ) Depreciation and amortization expense (640 ) (1 ) (641 ) Segment Performance $ (964 ) $ (721 ) (1,685 ) Share-based compensation (170 ) (170 ) Financial income, net 1,772 1,772 Loss before income taxes (83 )
Schedule of Revenues from Major Customers [Table Text Block]	Three months ended February 29, 2016 (in thousands) Customer A $ 764 Customer B $ 562

CONVERTIBLE LOAN AGREEMENTS (Ta

CONVERTIBLE LOAN AGREEMENTS (Tables)	3 Months Ended
	Feb. 29, 2016
Schedule of Fair Value of Instruments as of Closing Date [Table Text Block]	Total Fair Value (in thousands) Warrants component $ 323 Price protection derivative component 34 Shares component 616 Total $ 973

EQUITY (Tables)

EQUITY (Tables)	3 Months Ended
	Feb. 29, 2016
Schedule of Fair Value of Instruments for Financing [Table Text Block]	Total Fair Value (in thousands) Warrants component $ 67 Price protection derivative component 9 Shares component 149 Total $ 225

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	3 Months Ended
	Feb. 29, 2016
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended February 29, February 28, 2016 2015 (in thousands, except per share data) Basic: Income (loss) for the period $ 225 $ (790 ) Weighted average number of common shares outstanding 103,127,025 55,735,394 Earning (loss) per common share $ 0.002 $ (0.01 ) Diluted Income (loss) for the period $ 225 (790 ) Changes in fair value of embedded (104 ) Change in fair value of warrants 153 Income (loss) for the period $ 121 (943 ) Weighted average number of shares 103,127,025 55,735,394 Number of dilutive shares related to warrants 553,543 Weighted average number of common shares outstanding 103,127,025 56,288,937 Earning (loss) per common share $ 0.001 $ (0.02 )

FAIR VALUE PRESENTATION (Tables

FAIR VALUE PRESENTATION (Tables)	3 Months Ended	12 Months Ended
	Feb. 29, 2016	Nov. 30, 2015
Schedule of Assets and Liabilities at Fair Value [Table Text Block]	February 29, November 30, 2016 2015 Level 3 Level 3 Warrants (1) $ 1,450 $ 1,382 Price protection derivative (1) 197 1,533 Embedded derivatives*(1) 177 289 Convertible bonds (2) $ 1,787 $ 1,888
Schedule of Fair Value, Assumptions Used [Table Text Block]	Price Protection Embedded Derivative and Derivative Warrants Fair value of shares of common stock $ 0.33 $ 0.33 Expected volatility 84% - 89% 84% Discount on lack of marketability 13% - Risk free interest rate 0.38% - 0.9% 0.38% Expected term (years) 0.7 - 2.9 0.33 Expected dividend yield 0% 0% Expected capital raise dates Q2 2016,Q3 2016, Q1 2018	Price Protection Derivative and Embedded Convertible Warrants Derivative Bonds Fair value of shares of common stock $ 0.33 $ 0.33 $ 0.33 Expected volatility 87% - 98% 87% 88% Discount on lack of marketability 14% - 18% Risk free interest rate 0.44% - 1.24% 0.11% - 0.49% 0.42% Expected term (years) 0.9 - 3 0.08 - 0.87 0.8 Expected dividend yield 0% 0% 0% Expected capital raise dates Q2 2016-Q4 2016, Q4 2017
Schedule of Sensitivity Analysis of Fair Value, Warrants [Table Text Block]	Base -10% Base Base+10% (in thousands) As of February 29, 2016 $ 1,268 $ 1,450 $ 1,618
Schedule of Sensitivity Analysis of Changes in Fair Value, Derivatives [Table Text Block]	Base -10% Base Base+10% (in thousands) As of February 29, 2016 $ 192 $ 196 $ 199
Schedule of Sensitivity Analysis of Changes in Fair Value, Embedded Derivatives [Table Text Block]	Base -10% Base Base+10% (in thousands) As of February 29, 2016 $ 168.1 $ 177 $ 185.8
Schedule of Fair Value of Financial Liabilities, Activity [Table Text Block]	Price Embedded Convertible Protection Warrants Derivatives Bonds Derivative (in thousands) Balance at beginning of the period $ 1,382 $ 289 $ 1,888 $ 1,533 Additions 390 43 Conversion (10 ) Changes in fair value during the period (322 ) (102 ) (157 ) (1,379 ) Translation adjustments 56 Balance at end of the period $ 1,450 $ 177 $ 1,787 $ 197	Price Embedded Convertible Protection Warrants Derivatives Bonds Derivative (in thousands) Balance at beginning of the year $ 560 $ 992 $ - $ - Additions 1,390 112 3,234 1,526 Changes in fair value related to warrants expired* (525 ) 7 Changes in fair value during the period (43 ) (814 ) (1,221 ) Translation adjustments (125 ) Balance at end of the year $ 1,382 $ 289 $ 1,888 $ 1,533

GENERAL AND BASIS OF PRESENTA22

GENERAL AND BASIS OF PRESENTATION (Narrative) (Details) $ in Millions	3 Months Ended
	Feb. 29, 2016USD ($)
General And Basis Of Presentation 1	$ 20.4

ACQUISITION OF MASTHERCELL (Nar

ACQUISITION OF MASTHERCELL (Narrative) (Details) $ / shares in Units, $ in Thousands, pure in Millions	3 Months Ended
	Feb. 29, 2016USD ($)$ / sharesshares
Acquisition Of Masthercell 1	42,401,724
Acquisition Of Masthercell 2 | $ / shares	$ 0.58
Acquisition Of Masthercell 3 | $	$ 24,593
Acquisition Of Masthercell 4	8,173,483
Acquisition Of Masthercell 5	3.8
Acquisition Of Masthercell 6	1.2

SEGMENT INFORMATION (Narrative)

SEGMENT INFORMATION (Narrative) (Details)	3 Months Ended
	Feb. 29, 2016
Segment Information 1	1
Segment Information 2	10.00%

CONVERTIBLE LOAN AGREEMENTS (Na

CONVERTIBLE LOAN AGREEMENTS (Narrative) (Details)	3 Months Ended
	Feb. 29, 2016USD ($)shares
Convertible Loan Agreements 1	$ 950,000
Convertible Loan Agreements 2	6.00%
Convertible Loan Agreements 3	$ 0.52
Convertible Loan Agreements 4 | shares	1,870,638
Convertible Loan Agreements 5 | shares	1,870,638
Convertible Loan Agreements 6	$ 0.52

COMMITMENTS (Narrative) (Detail

COMMITMENTS (Narrative) (Details) $ in Millions	3 Months Ended
	Feb. 29, 2016USD ($)d
Commitments 1	50.00%
Commitments 2	50.00%
Commitments 3 | d	30
Commitments 4	$ 2
Commitments 5	$ 1

EQUITY (Narrative) (Details)

EQUITY (Narrative) (Details)	3 Months Ended
	Feb. 29, 2016USD ($)$ / sharesshares
Equity 1 | shares	432,693
Equity 2 | shares	432,693
Equity 3	$ 0.52
Equity 4	225,000
Equity 5	$ 0.52
Equity 6 | $ / shares	$ 0.52

LOSS PER SHARE (Narrative) (Det

LOSS PER SHARE (Narrative) (Details)	3 Months Ended
	Feb. 29, 2016shares
Loss Per Share 1	12,899,314
Loss Per Share 2	17,933,512
Loss Per Share 3	1,100,000
Loss Per Share 4	15,267,559
Loss Per Share 5	350,000
Loss Per Share 6	2,682,256
Loss Per Share 7	701,796

FAIR VALUE PRESENTATION (Narrat

FAIR VALUE PRESENTATION (Narrative) (Details)	3 Months Ended
	Feb. 29, 2016shares
Fair Value Presentation 1	6.00%
Fair Value Presentation 2	1,826,718

SUBSEQUENT EVENTS (Narrative) (

SUBSEQUENT EVENTS (Narrative) (Details)	3 Months Ended
	Feb. 29, 2016USD ($)$ / sharesshares
Subsequent Events 1 | shares	769,232
Subsequent Events 2 | shares	769,232
Subsequent Events 3	$ 0.52
Subsequent Events 4	400,000
Subsequent Events 5	$ 0.52
Subsequent Events 6 | $ / shares	$ 0.52
Subsequent Events 7	1,304,000
Subsequent Events 8	55.00%
Subsequent Events 9	717,000

Schedule of Segment Information

Schedule of Segment Information (Details)	3 Months Ended
	Feb. 29, 2016USD ($)
Segment Information Schedule Of Segment Information 1	$ 1,571
Segment Information Schedule Of Segment Information 2	(51)
Segment Information Schedule Of Segment Information 3	1,520
Segment Information Schedule Of Segment Information 4	(1,288)
Segment Information Schedule Of Segment Information 5	119
Segment Information Schedule Of Segment Information 6	(1,169)
Segment Information Schedule Of Segment Information 7	(298)
Segment Information Schedule Of Segment Information 8	(68)
Segment Information Schedule Of Segment Information 9	(366)
Segment Information Schedule Of Segment Information 10	(607)
Segment Information Schedule Of Segment Information 11	(422)
Segment Information Schedule Of Segment Information 12	(1,029)
Segment Information Schedule Of Segment Information 13	(640)
Segment Information Schedule Of Segment Information 14	(1)
Segment Information Schedule Of Segment Information 15	(641)
Segment Information Schedule Of Segment Information 16	(964)
Segment Information Schedule Of Segment Information 17	(721)
Segment Information Schedule Of Segment Information 18	(1,685)
Segment Information Schedule Of Segment Information 19	(170)
Segment Information Schedule Of Segment Information 20	(170)
Segment Information Schedule Of Segment Information 21	1,772
Segment Information Schedule Of Segment Information 22	1,772
Segment Information Schedule Of Segment Information 23	$ (83)

Schedule of Revenues from Major

Schedule of Revenues from Major Customers (Details)	3 Months Ended
	Feb. 29, 2016USD ($)
Segment Information Schedule Of Revenues From Major Customers 1	$ 764
Segment Information Schedule Of Revenues From Major Customers 2	$ 562

Schedule of Fair Value of Instr

Schedule of Fair Value of Instruments as of Closing Date (Details)	3 Months Ended
	Feb. 29, 2016USD ($)
Convertible Loan Agreements Schedule Of Fair Value Of Instruments 1	$ 323
Convertible Loan Agreements Schedule Of Fair Value Of Instruments 2	34
Convertible Loan Agreements Schedule Of Fair Value Of Instruments 3	616
Convertible Loan Agreements Schedule Of Fair Value Of Instruments 4	$ 973

Schedule of Fair Value of Ins34

Schedule of Fair Value of Instruments for Financing (Details)	3 Months Ended
	Feb. 29, 2016USD ($)
Equity Schedule Of Fair Value Of Instruments For Financing 1	$ 67
Equity Schedule Of Fair Value Of Instruments For Financing 2	9
Equity Schedule Of Fair Value Of Instruments For Financing 3	149
Equity Schedule Of Fair Value Of Instruments For Financing 4	$ 225

Schedule of Earnings Per Share,

Schedule of Earnings Per Share, Basic and Diluted (Details)	3 Months Ended
	Feb. 29, 2016USD ($)
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 1	$ 225
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 2	(790)
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 3	103,127,025
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 4	$ 55,735,394
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 5	0.002
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 6	(0.01)
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 7	$ 225
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 8	(790)
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 9	(104)
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 10	153
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 11	121
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 12	(943)
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 13	103,127,025
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 14	55,735,394
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 15	553,543
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 16	103,127,025
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 17	$ 56,288,937
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 18	0.001
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 19	(0.02)

Schedule of Assets and Liabilit

Schedule of Assets and Liabilities at Fair Value (Details)	3 Months Ended
	Feb. 29, 2016USD ($)
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 1	$ 1,450
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 2	1,382
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 3	197
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 4	1,533
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 5	177
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 6	289
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 7	1,787
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 8	$ 1,888

Schedule of Fair Value, Assumpt

Schedule of Fair Value, Assumptions Used (Details)	3 Months Ended	12 Months Ended
	Feb. 29, 2016	Nov. 30, 2015USD ($)
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 1	0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 2	0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 3	84.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 4	89.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 5	84.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 6	13.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 7	0
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 8	0.38%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 9	0.9
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 10	0.38%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 11	0.7
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 12	2.9
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 13	0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 14	0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 15	0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 1		0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 2		0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 3		0.33
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 4		87.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 5		98.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 6		87.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 7		88.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 8		14.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 9		$ 0
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 10		18.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 11		0.44%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 12		1.24%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 13		0.11%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 14		0.49%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 15		0.42%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 16		0.9
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 17		$ 3
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 18		0.08
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 19		0.87
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 20		0.8
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 21		0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 22		0.00%
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 23		0.00%

Schedule of Sensitivity Analysi

Schedule of Sensitivity Analysis of Fair Value, Warrants (Details)	3 Months Ended
	Feb. 29, 2016USD ($)
Fair Value Presentation Schedule Of Sensitivity Analysis Of Fair Value, Warrants 1	$ 1,268
Fair Value Presentation Schedule Of Sensitivity Analysis Of Fair Value, Warrants 2	1,450
Fair Value Presentation Schedule Of Sensitivity Analysis Of Fair Value, Warrants 3	$ 1,618

Schedule of Sensitivity Analy39

Schedule of Sensitivity Analysis of Changes in Fair Value, Derivatives (Details)	3 Months Ended
	Feb. 29, 2016USD ($)
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Derivatives 1	$ 192
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Derivatives 2	196
Fair Value Presentation Schedule Of Sensitivity Analysis Of Changes In Fair Value, Derivatives 3	$ 199

Schedule of Sensitivity Analy40

Schedule of Sensitivity Analysis of Changes in Fair Value, Embedded Derivatives (Details)	3 Months Ended
	Feb. 29, 2016USD ($)
Fair Value Presentation Schedule Of Sensitivity Analysis In Fair Value, Embedded Derivatives 1	168.1
Fair Value Presentation Schedule Of Sensitivity Analysis In Fair Value, Embedded Derivatives 2	$ 177
Fair Value Presentation Schedule Of Sensitivity Analysis In Fair Value, Embedded Derivatives 3	185.8

Schedule of Fair Value of Finan

Schedule of Fair Value of Financial Liabilities, Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Feb. 29, 2016	Nov. 30, 2015
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 1	$ 1,382
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 2	289
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 3	1,888
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 4	1,533
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 5	390
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 6	43
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 7	(10)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 8	(322)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 9	(102)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 10	(157)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 11	(1,379)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 12	56
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 13	1,450
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 14	177
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 15	1,787
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 16	$ 197
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 1		$ 560
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 2		992
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 3		0
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 4		0
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 5		1,390
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 6		112
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 7		3,234
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 8		1,526
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 9		(525)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 10		7
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 11		(43)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 12		(814)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 13		(1,221)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 14		(125)
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 15		1,382
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 16		289
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 17		1,888
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 18		$ 1,533